The effects of 5-fluoruracil treatment on 3'-fluoro-3'-deoxythymidine (FLT) transport and metabolism in proliferating and non-proliferating cultures of human tumor cells

Nuclear Medicine and Biology

Volumn 39, Issue 7, 2012, Pages 970-976

  Plotnik, David A ^a   McLaughlin, Lena J ^a   Krohn, Kenneth A ^a   Schwartz, Jeffrey L ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

5 Fluorouracil; ENT1; FLT PET Imaging; Nucleoside Metabolism

Indexed keywords

3' FLUOROTHYMIDINE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; FLUOROURACIL; THYMIDYLATE SYNTHASE;

ARTICLE; CANCER CELL CULTURE; CELL COUNT; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; NUCLEOSIDE METABOLISM; NUCLEOSIDE TRANSPORT; PROTEIN METABOLISM;

ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DIDEOXYNUCLEOSIDES; FLUOROURACIL; HUMANS; THYMIDINE KINASE;

EID: 84866009596     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2012.03.009     Document Type: Article

References (35)

1. Been L.B., Suurmeijer A.J., Cobben D.C., Jager P.L., Hoekstra H.J., Elsinga P.H. [18F]FLT-PET in oncology: current status and opportunities. Eur J Nucl Med Mol Imaging 2004, 31:1659-1672.
2. Larson S.M., Schoder H. New PET tracers for evaluation of solid tumor response to therapy. Q J Nucl Med Mol Imaging 2009, 53:158-166.
3. Shields A.F. Positron emission tomography measurement of tumor metabolism and growth: its expanding role in oncology. Mol Imaging Biol 2006, 8:141-150.
4. Rasey J.S., Grierson J.R., Wiens L.W., Kolb P.D., Schwartz J.L. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 2002, 43:1210-1217.
5. Ke P.Y., Kuo Y.Y., Hu C.M., Chang Z.F. Control of dTTP pool size by anaphase promoting complex/cyclosome is essential for the maintenance of genetic stability. Genes Dev 2005, 19:1920-1933.
6. Ke P.Y., Yang C.C., Tsai I.C., Chang Z.F. Degradation of human thymidine kinase is dependent on serine-13 phosphorylation: involvement of the SCF-mediated pathway. Biochem J 2003, 370:265-273.
7. Schwartz J.L., Tamura Y., Jordan R., Grierson J.R., Krohn K.A. Effect of p53 activation on cell growth, thymidine kinase-1 activity, and 3'-deoxy-3'fluorothymidine uptake. Nucl Med Biol 2004, 31:419-423.
8. Plotnik D.A., Emerick L.E., Krohn K.A., Unadkat J.D., Schwartz J.L. Different modes of transport for 3H-thymidine, 3H-FLT, and 3H-FMAU in proliferating and nonproliferating human tumor cells. J Nucl Med 2010, 51:1464-1471.
9. Paproski R.J., Ng A.M., Yao S.Y., Graham K., Young J.D., Cass C.E. The role of human nucleoside transporters in uptake of 3'-deoxy-3'-fluorothymidine. Mol Pharmacol 2008, 74:1372-1380.
10. Paproski R.J., Wuest M., jans H-S, Graham K., Gati W.P., McQuarrie S., et al. Biodistribution and Uptake of 3'-Deoxy-3'-Fluorothymidine in ENT1-Knockout Mice and in an ENT1-Knockdown Tumor Model. J Nucl Med 2010, 51:1447-1455.
11. Paproski R.D., Young J.D., Cass C.E. Predicting gemcitabine transport and toxicity in human pancreatic cancer cell lines with the positron emission tomography tracer 3'-deoxy-3'-fluorothymidine. Biochem Pharmacol 2010, 79:587-595.
12. Plotnik D.A, McLaughlin L.J., Chan J., Redmayne-Titley J.N., Schwartz J.L. The role of nucleoside/nucleotide transport and metabolism in the uptake and retention of 3'-fluoro-3'-deoxythymidine in human B-lymphoblast cells. Nucl Med Biol. 2011, 38:979-986.
13. Grierson J.R., Schwartz J.L., Muzi M., Jordan R., Krohn K.A. Metabolism of 3'-deoxy-3'-[F-18]fluorothymidine in proliferating A549 cells: validations for positron emission tomography. Nucl Med Biol 2004, 31:829-837.
14. Danenberg P.V., Malli H., Swenson S. Thymidylate synthase inhibitors. Semin Oncol 1999, 26:621-631.
15. Aschele C., Lonardi S., Monfardini S. Thymidylate synthase expression as a predictor of clinical response to fluoropyrimidine-based chemotherapy in advanced colorectal cancer. Cancer Treat Rev 2002, 28:27-47.
16. Banerjee D., Mayer-Kuckuk P., Capiaux G., Budak-Alpdogan T., Gorlick R., Bertino J.R. Novel aspects of resistance to drugs targeted to dihydrofolate reductase and thymidylate synthase. Biochim Biophys Acta 2002, 1587:164-173.
17. Bavetsias V., Jackman A.L., Marriott J.H., Kimbell R., Gibson W., Boyle F.T., et al. Folate-based inhibitors of thymidylate synthase: synthesis and antitumor activity of gamma-linked sterically hindered dipeptide analogues of 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583). J Med Chem 1997, 40:1495-1510.
18. Ceppi P., Papotti M., Scagliotti G. New strategies for targeting the therapy of NSCLC: the role of ERCC1 and TS. Adv Med Sci. 2010, 55:22-25.
19. Gmeiner W.H. Novel chemical strategies for thymidylate synthase inhibition. Curr Med Chem 2005, 12:191-202.
20. Jackman A.L. Inhibition of thymidylate synthase: biochemical pharmacology of drugs with activity in colorectal cancer. Tumori 1997, 83:S65-S66.
21. Pinedo H.M., Peters G.F. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1988, 6:1653-1664.
22. Pressacco J., Mitrovski B., Erlichman C., Hedley D.W. Effects of thymidylate synthase inhibition on thymidine kinase activity and nucleoside transporter expression. Cancer Res 1995, 55:1505-1508.
23. Pillai R.G., Forster M., Perumal M., Mitchell F., Leyton J., Aibgirhio F.I., et al. Imaging pharmacodynamics of the alpha-folate receptor-targeted thymidylate synthase inhibitor BGC 945. Cancer Res 2008, 68:3827-3834.
24. Wells P., Aboagye E., Gunn R.N., Osman S., Boddy A.V., Taylor G.A., et al. 2-[11C]thymidine positron emission tomography as an indicator of thymidylate synthase inhibition in patients treated with AG337. J Natl Cancer Inst 2003, 95:675-682.
25. Yau K., Price P., Pillai R.G., Aboagye E. Elevation of radiolabelled thymidine uptake in RIF-1 fibrosarcoma and HT29 colon adenocarcinoma cells after treatment with thymidylate synthase inhibitors. Eur J Nucl Med Mol Imaging 2006, 33:981-987.
26. Barthel H., Cleij M.C., Collingridge D.R., Hutchinson O.C., Osman S., He Q., et al. 3'-deoxy-3'-[18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 2003, 63:3791-3798.
27. Direcks W.G., Berndsen S.C., Proost N., Peters G.J., Balzarini J., Spreeuwenberg M.D., et al. [18F]FDG and [18F]FLT uptake in human breast cancer cells in relation to the effects of chemotherapy: an in vitro study. Br J Cancer 2008, 99:481-487.
28. Dittmann H., Dohmen B.M., Kehlbach R., Bartusek G., Pritzkow M., Sarbia M., et al. Early changes in [18F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging 2002, 29:1462-1469.
29. Perumal M., Pillai R.G., Barthel H., Leyton J., Latigo J.R., Forster M., et al. Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography. Cancer Res 2006, 66:8558-8564.
30. Kenny L.M., Contractor K.B., Stebbing J., Al-Nahhas A., Palmieri C., Shousha S., et al. Altered tissue 3'-deoxy-3'-[18F]fluorothymidine pharmacokinetics in human breast cancer following capecitabine treatment detected by positron emission tomography. Clin Cancer Res 2009, 15:6649-6657.
31. Lee S.J., Kim S.Y., Chung J.H., Oh S.J., Ryu J.S., Hong Y.S., et al. Induction of thymidine kinase 1 after 5-fluorouracil as a mechanism for 3'-deoxy-3'-[18F]fluorothymidine flare. Biochem Pharmacol 2010, 80:1528-1536.
32. Schwartz J.L., Tamura Y., Jordan R., Grierson J.R., Krohn K.A. Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J Nucl Med 2003, 44:2027-2032.
33. Robinson H.M., Jones R., Walker M., Zachos G., Brown R., Cassidy J., et al. Chk1-dependent slowing of S-phase progression protects DT40 B-lymphoma cells against killing by the nucleoside analogue 5-fluorouracil. Oncogene 2006, 25:5359-5369.
34. Xiao Z., Xue J., Sowin T.J., Rosenberg S.H., Zhang H. A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation. Oncogene 2005, 24:1403-1411.
35. Yoshioka A., Tanaka S., Hiraoka O., Koyama Y., Hirota Y., Ayusawa D., et al. Deoxyribonucleoside triphosphate imbalance. 5-Fluorodeoxyuridine-induced DNA double strand breaks in mouse FM3A cells and the mechanism of cell death. J Biol Chem 1987, 262:8235-8241.